Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03203304 · ClinicalTrials.gov registry record · Phase 1
Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer
A Phase 1 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT03203304 is a Phase 1 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 14 participants.
The verdict
NCT03203304, a Phase 1 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
External beam photon stereotactic body radiotherapy (SBRT) using a linear accelerator to a total dose of 40 Gy in 5 fractions delivered once daily with at least 48 hours between each fraction. SBRT treatment will be completed within a 21-day window. Starting within 14 days after completion of SBRT, intravenous nivolumab 240 mg will be given every 2 weeks as monotherapy or in combination with ipilimumab 1 mg/kg IV every 6 weeks.
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2017-08-25 |
| Est. Completion | 2019-03-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03203304
The ClinicalTrials.gov registry entry for NCT03203304 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT03203304 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03203304 about?
NCT03203304 is a clinical study titled "Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer". External beam photon stereotactic body radiotherapy (SBRT) using a linear accelerator to a total dose of 40 Gy in 5 fractions delivered once daily with at least 48 hours between each fraction. SBRT treatment will be completed within a 21-day window. Starting within 14 days after completion of SBRT, ...
What is the current status of trial NCT03203304?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2017-08-25. Estimated completion is 2019-03-13.
What interventions are being tested in trial NCT03203304?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT03203304?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.